You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Investigational Drug Information for Ensifentrine


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Ensifentrine?

Ensifentrine is an investigational drug.

There have been 8 clinical trials for Ensifentrine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 22nd 2020.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and Nuance Pharma (shanghai) Co., Ltd.

There are twenty-two US patents protecting this investigational drug and three hundred and forty-eight international patents.

Recent Clinical Trials for Ensifentrine
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese SubjectsNuance Pharma (shanghai) Co., LtdPhase 1
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseLaboratory Corporation of AmericaPhase 3
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNuance Pharma (shanghai) Co., LtdPhase 3

See all Ensifentrine clinical trials

Clinical Trial Summary for Ensifentrine

Top disease conditions for Ensifentrine
Top clinical trial sponsors for Ensifentrine

See all Ensifentrine clinical trials

US Patents for Ensifentrine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ensifentrine ⤷  Sign Up Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU) ⤷  Sign Up
Ensifentrine ⤷  Sign Up Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Sign Up
Ensifentrine ⤷  Sign Up Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Sign Up
Ensifentrine ⤷  Sign Up Salt of a pyrimido[6,1-A]isoquinolin-4-one compound VERONA PHARMA PLC (Cardiff, GB) ⤷  Sign Up
Ensifentrine ⤷  Sign Up Method of preventing hair loss or promoting hair growth by using phosphodiesterase 3 inhibitor SEOUL NATIONAL UNIVERSITY HOSPITAL (Seoul, KR) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ensifentrine

Drugname Country Document Number Estimated Expiration Related US Patent
Ensifentrine Australia AU2013227351 2032-02-28 ⤷  Sign Up
Ensifentrine Australia AU2016202881 2032-02-28 ⤷  Sign Up
Ensifentrine Australia AU2017213466 2032-02-28 ⤷  Sign Up
Ensifentrine Canada CA2865702 2032-02-28 ⤷  Sign Up
Ensifentrine China CN104703584 2032-02-28 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.